特比萘芬在浅表真菌感染中的临床应用

摘要/Abstract

摘要：

特比萘芬是治疗皮肤浅表真菌感染的主要药物之一，是皮肤癣菌感染的一线治疗药物。上市至今，在甲真菌病、头癣、体股癣、手足癣等浅表真菌感染中，有极为广泛的临床应用，是一种安全有效的治疗药物。对某些皮肤黏膜念珠菌感染也有疗效。

Abstract:

Terbinafine is the major antifungal agent usedforthe treatment of superficial mycosis, especially used as a first-line therapeutic choice for dermatophyte infection. In nearly three decades, terbinafine had been proved to be highly effective and safe for onychomycosis, tinea capitis, tinea corporis and cruris, tinea manus and pedis through widely clinical application. It also showed efficiency in some mucocutaneous candidosis cases.

Key words: terbinafine, superficial mycosis, dermatophyte

中图分类号:

R978.5

朱红梅, 温海. 特比萘芬在浅表真菌感染中的临床应用[J]. 中国真菌学杂志, 2020, 15(5): 297-303.

ZHU Hong-mei, WEN Hai. Clinical application of terbinafine in the treatment of superficial mycosis[J]. Chinese Journal of Mycology, 2020, 15(5): 297-303.

参考文献 59

[1]	Korting HC, Kiencke P, Nelles S, etal. Comparable efficacy and safety of various topical formulations of terbinafine in tineapedis irrespective of the treatment regimen:results of a meta-analysis[J].Am J Clin Dermatol, 2007,8(6):357-364.
[2]	James IG,Loria-Kanza Y, Jones TC.Short-duration topical treatment of tineapedis using terbinafine emulsion gel:results of a dose-ranging clinical trial[J]. J Dermatolog Treat, 2007,18(3):163-168.
[3]	Li RY, Wang AP,Xu JH,et al.Efficacy and safety of 1% terbinafine film-forming solution in Chinese patients with tinea pedis:a randomized, double-blind, placebo-controlled, multicenter, parallel-group study[J].Clin Drug Investig, 2014, 34(3):223-230.
[4]	Brown M, Evans C, Muddle A,et al. Efficacy, tolerability and consumer acceptability of terbinafine topical spray versus terbinafine topical solution:a phase IIa, randomised, observer-blind, comparative study[J]. Am J Clin Dermatol, 2013,14(5):413-419.
[5]	Baudraz-Rosselet F, Rakosi T, Wili PB, et al. Treatment of onychomycosis with terbinafine[J]. Br J Dermatol, 1992,126(suppl 39):40-46.
[6]	McClellan KJ, WisemanLR,Markham A. Terbinafine:An update of its use in superficial mycoses[J]. Drugs, 1999,58(1):179-202.
[7]	Auvinen T, Tiihonen R, Soini M,et al.Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis:a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial[J]. Br J Dermatol, 2015,173(4):940-948.
[8]	Elewski B, Pollak R, Ashton S,et al. A randomized, placebo-and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis[J]. Br J Dermatol, 2012,166(2):389-398.
[9]	Gupta AK, Lynch LE,Kogan N,et al. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis[J]. J Eur Acad Dermatol Venereol, 2009, 23(3):256-262.
[10]	Gupta AK, Foley KA, Mays RR,et al.Monotherapy for toenail onychomycosis:a systematic review and network meta-analysis[J]. Br J Dermatol, 2020,182(2):287-299.
[11]	Gupta AK,Stec N, Bamimore MA,et al.The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis[J]. J Eur Acad Dermatol Venereol, 2020,34(3):580-588.
[12]	Gupta AK,Sibbald RG, AndriessenA,et al.Toenail onychomycosis-A Canadian approach with a new transungual treatment:development of a clinical pathway[J]. J Cutan Med Surg, 2015, 19(5):440-449.
[13]	Ranawaka RR, Nagahawatte A, Gunasekara TA,et al.Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis:A study with 90 patients[J]. J Dermatolog Treat, 2016,27(4):364-372.
[14]	Abu El-Hamd M, Abd Elhameed MI, Shalaby MFM,et al. In vitro antifungal susceptibility testing of fungi in patients with onychomycosis[J]. Dermatol Ther, 2020, 33(3):e13429. doi:10.1111/dth.13429. Online ahead of print.
[15]	Leung AKC, Hon KL, Leong KF,et al.Tinea capitis:an updated review[J]. Recent Pat Inflamm Allergy Drug Discov, 2020,14(1):58-68.
[16]	中国头癣诊疗指南工作组.中国头癣诊断和治疗指南(2018修订版)[J].中国真菌学杂志,2019,14(1):4-6
[17]	Drago L, Micali G, Papini M, et al. Management of mycoses in daily practice[J].G Ital Dermatol Venereol, 2017, 152(6):642-650.
[18]	Mercurio MG, E1ewski BE. Tinea capitis treatment[J]. Dennatol Ther, 1997,3:79-83.
[19]	Fuller LC, Barton RC,Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of tinea capitis 2014[J]. Br J Dermatol, 2014,171:454-463.
[20]	Kakourou T, Uksal U, European Society for Pediatric Dermatology.Guidelines for the management of tinea capitis in children[J]. Pediatr Dermatol, 2010,27(3):226-228.
[21]	Devliotou-Panagiotidou D, Koussidou-Eremondi TH. Efficacy and tolerability of 8 weeks' treatment with terbinafine in children with tinea capitis caused by Microsporum Canis:A comparison of Three Doses[J].J Eur Acad Dermatol Venereol,2004,18(2):155-159.
[22]	Gupta AK, Mays RR,Versteeg SG,et al. Tinea capitis in children:a systematic review of management[J]. J Eur Acad Dermatol Venereol, 2018, 32(12):2264-2274.
[23]	Chen X, Jiang X, Yang M,et al.Systemic antifungal therapy for tinea capitis in children[J]. Cochrane Database Syst Rev, 2016,(5):CD004685.
[24]	Kunitake Y, Noguchi H, Hiruma M. Summarization of tinea capitis cases encountered at a clinic in the past 5 years[J].[Article in Japanese] Nihon Ishinkin Gakkai Zasshi, 2009, 50(3):161-166.
[25]	Shwayder T. Terbinafine[J]. J Am Acad Dermatol, 1998,39(1):136.
[26]	van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis:a summary of a Cochrane systematic review[J]. Br J Dermatol, 2015, 172(3):616-641.
[27]	中国体癣和股癣诊疗指南工作组.中国体癣和股癣诊疗指南(2018修订版)[J].中国真菌学杂志,2019,14(1):1-3.
[28]	Gupta AK, Foley KA,Versteeg SG. New antifungal agents and new formulations against dermatophytes[J]. Mycopathologia, 2017, 182(1-2):127-141.
[29]	Bhatia A,Kanish B, Badyal DK, et al. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin-A prospective, randomized comparative study[J]. Indian J Pharmacol, 2019,51(2):116-119.
[30]	Shiraki Y, Hiruma M, Inoue A,et al. A short-term treatment of tinea corporis and tinea cruris with oral terbinafine[J]. Nihon Ishinkin Gakkai Zasshi, 2003,44(2):121-125.
[31]	Rich P,Houpt KR, LaMarca A, et al. Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes[J]. Cutis, 2001,68(1 Suppl):15-22.
[32]	de Chauvin MF, Viguié-Vallanet C, Kienzler JL, et al. Novel, single-dose, topical treatment of tinea pedis using terbinafine:results of a dose-finding clinical trial[J]. Mycoses, 2008,51(1):1-6.
[33]	Brown M, Evans C, Muddle A,et al. Efficacy, tolerability and consumer acceptability of terbinafine topical spray versus terbinafine topical solution:a phase IIa, randomised, observer-blind, comparative study[J]. Am J Clin Dermatol, 2013, 14(5):413-419.
[34]	Schäfer-Korting M, Schoellmann C, Korting HC. Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis[J]. Skin Pharmacol Physiol, 2008,21(4):203-210.
[35]	中国中西医结合学会皮肤性病专业委员会真菌学组,中国医师协会皮肤科分会真菌亚专业委员会,中华医学会皮肤病分会真菌学组.手癣和足癣诊疗指南(2017修订版)[J].中国真菌学杂志,2017,12(6):321-324
[36]	Smith S,Houpt K, Rich P, et al. Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients[J]. Cutis, 2001,68(1 Suppl):30-39.
[37]	Takiuchi I, Morishita N, Hamaguchi T, et al.Treatment outcome and relapse with short-term oral terbinafine (250 mg/day) in tinea pedis[J]. Nihon Ishinkin Gakkai Zasshi, 2005,46(4):285-289.
[38]	Pyatski Y, Flach CR, Mendelsohn R. FT-IR investigation of terbinafine interaction with stratum corneum constituents[J]. Biochim Biophys Acta Biomembr, 2020, 1862(9):183335.
[39]	Kikuchi I,Tanuma H, Morimoto K, et al. Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic-type tinea pedis[J]. Mycoses, 2008,51(6):523-531.
[40]	White JE, Perkins PJ, Evans EG. Successful 2-week treatment withterbinafine (Lamisil) for moccasin tinea pedis and tinea manuum[J]. Br J Dermatol,1991,125(3):260-262.
[41]	Tausch I, Decroix J, Gwiezdzinski Z,et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus[J]. Int J Dermatol, 1998,37(2):140-142.
[42]	Hay RJ, McGregor JM,Wuite J, et al. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole100 mg/day in plantar-type tinea pedis[J]. Br J Dermatol,1995,132(4):604-608.
[43]	Shi TW, Zhang JA, Zhang XW, etal.Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis[J]. Mycoses, 2014,57(9):560-564.
[44]	Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis:2016 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016,62(4):e1-50.
[45]	Mendling W, Brasch J, Cornely OA, et al.Guideline:vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis)[J]. Mycoses, 2015,58(Suppl 1):1-15.
[46]	Katoh T. Guidelines for diagnosis and treatment of mucocutaneous candidiasis[J]. Nihon Ishinkin Gakkai Zasshi, 2009,50(4):207-212.[Article in Japanese]
[47]	Balfour JA,Faulds D.Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses[J].Drugs, 1992,43(2):259-284.
[48]	刘耕,于波.盐酸特比萘芬阴道泡腾片治疗念珠菌性阴道炎疗效观察[J]..中国真菌学杂志,2006,1(6):41-42.
[49]	JungEG,Haas PJ,Bräutigam M,et al. Systemic treatment of skin candidosis:A randomized comparison of terbinafine and ketoconazole[J]. Mycoses, 1994,37(9-10):361-365.
[50]	Ferahbas A, Koc AN, Uksal U, et al. Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis[J]. Am J Ther, 2006,13(4):332-336.
[51]	燕华玲,王爱平,万喆,等.特比萘芬对白念珠菌菌丝相和酵母相敏感性的比较[J].中华皮肤科杂志,2005,38(8):515.
[52]	Yassin MT, Mostafa AA, Al-Askar AA, et al. In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis[J]. Eur J Med Res, 2020, 25(1):1.
[53]	Shi XY, Yang YP, Zhang Y, et al. Molecular identification and antifungal susceptibility of 186Candida isolates from vulvovaginal candidiasis in southern China[J]. J Med Microbiol, 2015, 64(Pt 4):390-393.
[54]	Faergemann, J, Zehender H, Denouel J, et al. Levels of terbinafine in plasma, stratum-corneum,dermis-epidermis(without stratumcorneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for 4 weeks[J]. Acta Dermato-Venereol, 1993, 73:305-309.
[55]	秦晓华,王明贵,Kanafani ZA,等.抗真菌药物的耐药机制及其临床意义[J]. 中国感染与化疗杂志,2010,10(4):320.
[56]	Hsieh A,Quenan S, Riat A, et al.A new mutation in the SQLE gene of Trichophyton mentagrophytes associated to terbinafine resistance in a couple with disseminated tinea corporis[J]. J Mycol Med, 2019,29(4):352-355.
[57]	Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine:results of a postmarketing surveillance study in 25,884 patients[J]. Arch Dermatol, 1997,133(10):1213-1219.
[58]	Stolmeier DA, Stratman HB, McIntee TJ,et al. Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections[J]. JAMA Dermatol, 2018, 154(12):1409-1416.
[59]	Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration[J].J Dermatolog Treat,2020:1-5.[Epub ahead of print]